Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

23.27 -0.96 (-3.98%)
Streaming Delayed Price Updated: 2:13 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arvinas Inc

Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP) 
From Arvinas Inc.
Via GlobeNewswire
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Collaboration expands Carrick’s clinical-stage Oncology program 
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Stifel Targeted Oncology Day
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. 
Via MarketBeat
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Upcoming Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
From Arvinas Inc.
Via GlobeNewswire
Arvinas Gives Back to Local Greater New Haven Community
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute has been awarded a $25,000 monetary prize recognizing her innovation in the field of targeted protein degradation 
From Arvinas Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.